Replay available

Alkermes (NASDAQ:ALKS) Q1 2020 Earnings Call

Alkermes (NASDAQ:ALKS) Q1 2020 earnings call, held 2020-04-29. Watch the replay and read the transcript on 6ix.

Wed, April 29, 2020 at 8:00 AMendedReplay
Alkermes (NASDAQ:ALKS) Q1 2020 Earnings Call
Company
Alkermes PLC (NASDAQ:ALKS)
Period
Q1 2020 earnings call
Date
Wed, Apr 29, 2020, 8:00 AM ET
Replay
Watch the replay on this page · 1 h 8 min
Results news release
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update · Wed, Apr 29, 2020

On 6ix: 6ix.com/event/alkermes-plc-alks-q1-2020-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Greetings and welcome to the Alkermes first quarter 2020 financial results conference call. My name is Melissa and I will be your conference operator today. At this time, all participants are in a listen only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. Please note that this conference is being recorded. I'll now turn the conference over to Sandra Coombs, Vice President of Investor Relations. Sandy, you may begin.

0:26 Thank you. Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter ended March 31, 2020. With me today are Richard Pops, our CEO, Todd Nichols, our SVP of sales and marketing, and Jim Fradies, our CFO. During the Q&A session, we'll also be joined by Ian Brown, our SVP of finance. Before we begin, I encourage everyone to go to the investor section of alkermes.com to find our press release and related financial tables. including a reconciliation of the GAAP to non-GAAP financial measures that we'll discuss today. We believe the non-GAAP financial results in conjunction with the GAAP results are useful in understanding the ongoing economics of our business. Our discussions during this conference call will include forward-looking statements.

1:11 Actual results could differ materially from these forward-looking statements. Please see slide two of the accompanying presentation, our press release issued this morning, and our most recent annual and quarterly reports filed with the SEC for important risk factors that could cause our actual results to differ materially from those expressed or implied in the forward-looking statement. We undertake no obligation to update or revise the information provided on this call or in the accompanying presentation as a result of new information or future results or developments. After our prepared remarks, we'll open the call for Q&A. Now I'll turn the call over to Rich to provide an update on the company's response to the COVID-19 pandemic.

1:50 Thank you Sandy and good morning everybody. I hope everybody listening is well. So before getting to our first quarter results and an update on the business, I have to note the challenging circumstances caused by COVID-19. The acute and wide-ranging impact that this virus has had on health and economic well-being of our communities is significant. We activated quickly and with compassion to navigate these difficult conditions. and today Todd will provide a detailed review of the commercial impact we've observed particularly on Vivitrol in the first few weeks of April and our mitigation efforts. Jim will outline the potential implications for our financial results and discuss the impact on our ability to provide expectations for the balance of 2020.

2:35 In the face of this pandemic Alkermes has adapted our business practices so that we can continue to meet our public health responsibilities which have become even more pronounced. People living with serious mental illness and addiction, conditions that are often stigmatized and marginalized in our society, have an ongoing need for their medicines. Yet many are facing challenges in accessing their caregivers and the healthcare system. We are an active participant along with many other stakeholders in efforts to ensure that the treatment system continues to function for these patients, for their families and their communities. As we work together to navigate the rapidly evolving environment Our two main priorities are to protect the health of our employees and to ensure that the healthcare providers and patients have uninterrupted access to our medicines.

3:27 Our team organized quickly and our response has evolved over three distinct stages. In the first stage, we mobilized to change the way we do business to protect the well-being of our employees, implement physical distancing, and maintain business continuity. This included adopting work from home policies for those who could do their jobs remotely and for our field-based personnel transitioning to virtual healthcare provider engagement. We're the only manufacturer of several important medicines that patients rely on, including sterile injectables and complex solid oral dose forms. For our employees who continue to work on critical tasks in our manufacturing facilities and in our laboratories, We instituted additional safety precautions, including increased protective equipment, sanitization, and physical distancing practices.

4:18 In the second stage of our response, our focus expanded to preserving our ability to supply for the foreseeable future, one, commercial products to the patients that rely on Vivitrol and Ariscada, two, third-party products that we manufacture, and three, investigational products for our ongoing clinical trials. at this time we do not anticipate any supply interruptions however we and our critical supply chain partners are regularly assessing the situation and adapting as appropriate our focus extends beyond the manufacture of our medicines it's more important now than ever that we support people living with schizophrenia opioid dependence and alcohol dependence and help ensure that they have the information and the resources to help them access treatment Todd will outline some of our efforts to and other important patients and healthcare providers in this environment.

5:10 In the third stage of our response, we're focused on how we can find new, streamlined ways of working, eliminate unnecessary expenditures and gain a competitive advantage by being more agile in meeting the needs of our stakeholders. We have an opportunity to be creative and develop new best practices that can have a lasting and positive impact on the way we conduct our business. We recognize that this is a dynamic situation. are closely monitoring the latest information on COVID in order to make timely, informed decisions designed to protect the health of our employees, support uninterrupted access to our medicine, and continue the advancement of our research. So with that, I'll turn the call over to Todd for a review of our first quarter commercial performance and response to COVID-19 on the commercial front.

5:57 Thanks, Rich, and good morning, everyone. Coming into Q1, our commercial organization was focused on starting the year strong with a heightened sense of urgency to drive revenue and to continue to adapt to patient needs. We made steady progress against our commercial strategy this past quarter and our Q1 results reflect the initial success of these efforts as we achieved all-time highs in healthcare provider adoption for both Aristide and Vivitrol. As we entered the second quarter, we began to see the impact of the COVID-19 pandemic on our commercial portfolio. with a more pronounced impact on Vivitrol than Aristata. In the first few weeks of April, Vivitrol factory shipments have been approximately 25% lighter than our pre-COVID expectations.

6:45 However, it is too early to reliably extrapolate a trend forward given the dynamic situation. Aristata has not been impacted as much, but we have seen flattening in prescription data and factory shipments over the last few weeks. At this time, we can't predict with certainty what the duration or magnitude of the COVID impact will be across our commercial portfolio, but I will outline our efforts to adapt to the current environment following a discussion of our Q1 results. Starting with Vivitrol, net sales in the first quarter increased 14% year-over-year to 78.8 million, driven by 13% unit growth. The number of healthcare provider accounts prescribing Vivitrol increased approximately 10% year-over-year as we work to expand the Vivitrol provider network.

7:39 Due to the important overlay of policy and funding at the state level, Vivitrol's growth continued to be geographically driven. In the first quarter, our top five states represented 42% of net sales. Year-over-year growth for Q1 was driven by continued strength and growth in California, New York, and Florida and broad-based growth in states with lower Vivitrol share, with 20 states growing more than 25% year-over-year. Geographic diversification remains an important part of our long-term growth strategy. Vivitrol demand showed encouraging trends as we continue to diversify the business across alcohol dependence and opioid dependence, particularly in states where Vivitrol has experienced strong recent growth like California and Michigan, We saw greater contributions from the alcohol dependence indication.

8:31 Looking ahead, our strategy will continue to be guided by responding to patient needs, which is particularly important in the current environment as COVID-19 and efforts to contain its spread are disrupting access to care for some patients seeking addiction treatment services. For example, over the last three weeks, Vivitrol new patient starts have been under pressure. The more pronounced impact on new patient starts could be driven by a variety of factors, including the closure of certain addiction treatment centers, decreased access to detox services, and a decrease in patients' desire to seek care and ability to engage with health care providers. Of note, certain areas hit hardest and earliest by the pandemic in the United States, like New York, California, Massachusetts, are also top Vivitrol geographies.

9:24 We believe this alignment is augmenting the impact that we have seen on Vivitrol over the last three weeks. We will be monitoring trends in these geographies carefully in the weeks and months ahead. In response to COVID-19 challenges, we pivoted quickly to support the needs of our customers and protect the health and well-being of our employees. We rapidly transitioned our customer engagement strategy to a virtual model and focused on advancing our digital capabilities while continuing to support broad access to our medicines and the needs of healthcare providers and patients. To support providers, we are providing educational materials virtually while helping them navigate reimbursement for telehealth services. To support patients, we are highlighting our patient services resources, expanding our injection site network, and updating our provider locators to reflect these additional sites of care where patients can receive injections.

10:20 As an example, we recently engaged with Albertsons, which now offer access to injections at 900 of its on-site pharmacies, predominantly in the Midwest and West Coast regions. And we continue to engage with other potential injection providers to further expand patient access. We're monitoring the situation and will adopt additional measures to support access to treatment as appropriate. Turning to the Aristotle product family, net sales in the first quarter increased 70% year-over-year to 51 million. This growth reflects underlying demand and impact of inventory fluctuations in the first quarter of 2019. Underlying total prescription data for Aristata demonstrated solid growth of 43% year-over-year in terms of months of therapy.

11:11 In March 2020, Aristata's market share for new prescriptions in terms of months of therapy achieved an all-time high of 10% in the overall market for a long-acting atypical antipsychotics. Market share for new to brand prescriptions hit 13.2% in February 2020, the latest month of available data, which we believe is a useful leading indicator for the trajectory of growth for Aristata. The progress we are making reflects an intense focus on execution as we communicate the value proposition of Aristata and its differentiated positioning in the market. Heading into 2020, we sharpened our focus on driving utilization of the two-month 1064 dose and Aristata initio. Positive data from our phase three Alpine study, which we announced in the middle of last year and continue to roll out, is an important element of our strategy to drive awareness of the benefits of initio and the two-month dose among healthcare providers.

12:09 particularly within the context of reduced personal interactions we believe the two-month dose offering along with aristata initio has resonated with physicians with a differentiated product family a strong pair access profile and a compelling value proposition we have a clear opportunity to drive the growth of aristata in the future as i mentioned the impact of covid19 on aristata has been less pronounced than that seen with vivitrol but we have seen a flattening of weekly prescription data and wholesaler shipments to date in April. As an injectable medicine, Aristotle utilization relies on healthcare provider administration and it's too early to predict whether the pandemic and social distancing practices will have a measurable impact on patient access to Aristotle going forward.

13:01 Similar to Vivitrol, we are implementing strategies to support patients and healthcare providers including expanding our injection network and updating provider locators for Aristata. We're highlighting our patient access and support services and deploying virtual resources for HCPs and digital awareness campaigns. We believe these efforts will not only help mitigate potential disruptions but also present an opportunity to develop new and more efficient best practices that can be translated into competitive advantages over the long term. Turning to our launch preparations for 3831, which will be intensifying throughout the remainder of the year. We are planning for a spectrum of launch scenarios in the event that COVID-19 disruptions continue to present challenges and will work to navigate the evolving environment.

13:54 We expect the keys to a successful launch will remain awareness, Salesforce planning, and meaningful market access. As we prepare for launch, we have an opportunity to drive awareness through disease state education campaigns and scientific exchange. This includes presentations of 3831 data at a number of planned scientific congresses and some of which will take place in virtual formats. 3831 represents an important opportunity to capture operating efficiencies and maximize the value of our commercial infrastructure. With capabilities already in place in terms of access and reimbursement, medical affairs and marketing, our primary investment as we prepare for launch will be expanding our psychiatry field sales organization.

14:42 Currently, our field team is right-sized to address the concentrated universe of physicians driving utilization of long-acting injectables. To accommodate the broader footprint of prescribers for oral antipsychotics, across potential indications for both schizophrenia and bipolar 1 disorder, we plan to appropriately expand a field sales organization to meet the opportunity. We are evaluating a number of strategies and configurations and will be finalizing that sales force planning over the coming months. Establishing meaningful market access will be an important factor in driving early success of the launch. We have completed our contracting research, are updating our pricing research, and are developing engagement plans for key payers.

15:28 Moving forward, we remain deeply committed to serving the vulnerable populations that suffer from serious mental illness and addiction. Across the commercial portfolio, we are focused on execution and building new capabilities in this dynamic environment. We look forward to sharing our progress with you. And with that, I'll hand this over to Jim to provide our financial results for the quarter and an update on guidance.

15:52 Thank you, Todd, and good morning, everyone. I'm pleased to report solid first quarter results. We generated $246.2 million in total revenues driven by year over year growth in our proprietary products and our diverse revenue base. We recorded a gap net loss of $38.7 million and non gap net income of $1.7 million. I'll start with our key financial highlights for the quarter and then discuss the impact of COVID-19 on our business and financial outlook for 2020. Vivitrol net sales in the first quarter increased 14% year-over-year to $78.8 million, driven primarily by 13% unit growth. Gross to net adjustments of 49% in the quarter were comparable to the first quarter of 2019.

16:41 Consistent with seasonal patterns, Vivitrol net sales declined sequentially due primarily to the drawdown of the Q4 inventory build, as well as slightly higher gross to net adjustments. At the end of the first quarter, inventory levels were back within a normal range with just under two and a half weeks of inventory at our wholesaler and specialty pharmacies. Turning to the Aristada product family, net sales in the first quarter increased nearly 70% year over year to $51 million. This increase was driven by strong underlying demand and also the significant inventory drawdown that Aristada experienced in the first quarter of 2019. which reduced Aristada net sales in the same period last year. As Todd mentioned, we believe Aristada total prescription growth of 43% year over year in terms of months of therapy better represents underlying demand trends for Aristada.

17:36 Growth to net adjustments during the first quarter of 2020 were 51.8% as compared to 49% in Q1 2019, reflecting consolidation of certain Medicaid plans into broader buying consortiums. Sequentially, Aristata net sales declined due to the typical seasonal inventory patterns, as well as slightly higher gross-to-net adjustments. Inventory in the wholesale channel remains at roughly four weeks, which is a typical level for Aristata. Moving on to our manufacturing and royalty business, in the first quarter, our manufacturing and royalty revenues were $116.3 million, compared to $108.9 million in the same period in the prior year. driven primarily by long-acting injectable antipsychotics.

18:23 Revenues from Risperdal Consta, Invega Sistena, and Invega Trinza increased 9% year-over-year to $82.2 million, driven by increased end-market sales of Invega Sistena and Invega Trinza and the timing of manufacturing batches for Risperdal Consta. The growth in net sales of our proprietary commercial products and royalty in manufacturing revenues more than offset the decline in our R&D revenues, as a reimbursement of the development expenses for Brumerity from Biogen largely ended in the fourth quarter of last year with the approval of that product. In the first quarter of 2020, we recorded $243,000 of R&D revenues as compared to $14.7 million in Q1 2019. Turning to expenses, our total operating expenses were $283.6 million for the first quarter. down from $299.1 million in the same period in the prior year.

19:21 Our R&D expenses for the first quarter were $93.3 million compared to $102.6 million for the prior year, reflecting the completion of the Vimerity Development Program in 2019, which was somewhat offset by increased activity and patient enrollment in the ALCS 4230 Clinical Program. SG&A expenses for the first quarter were $133.4 million reflecting investment in the strong start initiatives related to Vivitrol and Aristotle growth and compares to $141.2 million for the prior year. Turning to our balance sheet, we ended the first quarter with approximately $550 million in cash and total investments compared to approximately $614 million at the end of 2019. The decrease is reflective of normal seasonal patterns in cash flows and changes in working capital.

20:15 The company's total debt outstanding was approximately $277 million at the end of the first quarter related to our term loan due in March 2023. I'll shift now to the impact of COVID-19 on our financial expectations for 2020. Today we're withdrawing our previously provided 2020 financial expectations due to the uncertainty surrounding COVID-19 disruptions to the healthcare system. While our first quarter results were in line with our operating plan and slightly ahead of our financial expectations, as the realities of the pandemic and the efforts to contain its spread intensified around the country in mid-March, as Todd mentioned, we began to see disruption in patient access to addiction treatment services and, to a lesser extent, treatment services for schizophrenia.

21:02 We expect that the impact of the COVID-19 on Alkermes Business will be driven primarily by the severity and duration of the pandemic. At this time, we're unable to reasonably predict the extent of the pandemic's impact on our future results as it crests across the country. We're monitoring demand on a daily basis and implementing mitigation strategies as Todd outlined. As we confront this pandemic, we're very focused on exercising financial discipline. We'll continue to analyze our cost base, make adjustments as we better understand the impact of the pandemic on our top line, and allocate our capital appropriately to areas where we see the highest potential return on investment. As we do our part in this evolving environment to protect the safety of our employees, support uninterrupted access of our products to healthcare providers and patients and facilitate business continuity, we continue to be in a position of financial strength.

22:00 With a diverse and well capitalized business, we believe we're well positioned to weather the impact of this pandemic with sufficient liquidity to advance our operating objectives and rebound when the public health responses allow. With that, I'll turn the call back over to Richard.

22:17 That's great. Thank you, Jim. And thank you, Todd. So as you've heard, we had a strong first quarter and we're adapting like everyone else to the COVID-19 environment. And while none of us has a clear sense of when the major disruptions will be behind us, we believe we have a resilient business and a plan to emerge from this even more focused. our research and development activities continue to advance our first priority is to support treatment continuity and ensure patient safety in our ongoing clinical trials we're in frequent communication with investigators and like other biopharmaceutical companies we are identifying ways to streamline study visits and enhance data collection to reduce burden on patients as well as on the investigative sites efforts like this have the potential to extend beyond the current environment and have a long-lasting positive impact on how clinical trials are conducted in the country.

23:13 Another priority is to keep advancing our most important programs, including initiating new clinical trial sites and protocols for our key investigational medicines. I'd say that ALKS 4230 in oncology is one of those. The potential for ALKS 4230 in both monotherapy and combination settings continues to be supported as the clinical data accumulates across our intravenous and subcutaneous dosing studies. Across what we call the artistry development program, March was our highest enrolling month. We continue to enroll patients in both artistry one and artistry two. We've seen a slowing of enrollment in April as some sites and investigators in our network have temporarily paused enrollment of new patients due to COVID-19.

24:00 which we expect will result in minor delays to those trials. Looking ahead, we expect activation of select ex-US sites primarily in the Asia Pacific region and Europe this quarter and we'll resume our plans to further expand our clinical trial network as soon as possible. With the resources and the capabilities to continue to advance 4230 at this stage of its development, we're focused on building the data set that will lead ultimately to broad-based collaboration. If 4230 lives up to its promise, we see collaborating as a key to maximally exploring its therapeutic potential for patients and driving value creation for shareholders. For ALCS 3831, our novel oral atypical antipsychotic, the NDA for schizophrenia and bipolar I disorder is currently under review at FDA with BDUFA target action date in November of this year.

24:57 We have not been made aware of any potential delays in the review timeline. The FDA recently communicated to us their intention to hold an advisory panel, although they've not yet shared details regarding the focus or format in the current environment. Because this NDA contains a new molecular entity and involves two different review divisions, we planned for an adcom and had been preparing since we submitted the application in November of last year. With the efficacy of olanzapine, and a differentiated tolerability profile, ALX3831 has the potential to be an important new treatment option, one that builds on the presence that we've built in schizophrenia with Aristata. The other area of intense scientific interest is our HDAC inhibitor platform.

25:43 That work largely remains on track. In order to maintain momentum and continuity of those efforts, our team has been innovative in geographically shifting work conducted by contract research organizations as COVID-19 has spread and peaked. Integration across research and early stage development has been critical as we prioritize the most high value experiments and continuously assess optimal internal and external sourcing options. Across the organization, innovation being brought forward and our people's ability to be nimble and adaptive in this environment is remarkable. I'm proud to see all that continues to be accomplished and I'm grateful for the resilience and dedication of our employees as we navigate these challenging times together.

26:30 We're focused on delivering on the key operational objectives to advance the business and build the value of the company. In responding to this crisis, the biopharmaceutical industry has the opportunity to demonstrate and underscore our immense value to society. Diagnostics, therapeutics, vaccines, these are the first order priorities for taming the pandemic. At Alkermes, we're focused on some of the most important health implications that can be exacerbated by social isolation, economic hardship, and fear. During and in the wake of the pandemic, care and treatment of serious mental illness and addiction will take on a new level of importance. We are very proud of the role we play to help people struggling with these disorders.

27:16 So I'll finish there and turn the call back to Sandy to run the Q&A.

27:21 Great. Thank you, Rich. Melissa, we'll now open the call for Q&A, please. Thank you. If you'd like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star key. Our first question comes from the line of Chris Shibutani with Cowan. Please proceed with your question. great thank you very much appreciate it you described the adaptations that you're working on in terms of the sales efforts including injection sites at places such as a pharmacy or Albertson can you quantify a little bit in terms of the extent to which you see that as being something that could be a go-forward option and particularly between opioid addiction versus the alcohol side which I think has been a very relevant part of your mixed shift efforts you had talked about maybe marketing more putting more emphasis on the alcohol treatment side.

28:24 Can you just maybe help put some shape for that? Thank you.

28:32 Yeah, Chris, let me spend, this is Todd, let me spend just a few minutes on that. To your point, we've spent a great deal of time and put a lot of thought over the last couple of weeks, more so probably the last month or so, thinking about how do we expand access to injections not only for Vivitrol but also for Aristata. In one of those areas clearly there's an opportunity with pharmacists and we're seeing that across the healthcare spectrum as well too. There's a lot of energy right now, a lot of acceptance of allowing pharmacists at the state level to practice at the top of their license and so we're working very closely at the policy level, at the state level as well and also with a lot of the major retailers having discussions regarding how do we expand access to injections.

29:23 It's very early I will tell you at this point right now we're excited about the situation that we have with Albertsons right now. It is early but we're seeing some really nice encouraging signs at the state level from you know other customers that have you know that are open to discussions like this and so we think that this is going to be a big part of delivering injectables similar to the way that vaccines are delivered in the long term. So although this is clearly an opportunity for us right now with the COVID situation, this will be a long-term opportunity for both products as well. So it's not just Vivitrol, it's Vivitrol and Aristata.

30:04 Hey Chris, this is Richard. I want to add on that because it's a bigger conversation we can have, but I think this may be one of the fundamental changes that derives from the pandemic. and it's not just retail pharmacies and the use of pharmacies for injection. It's the idea of telemedicine as a way of deploying psychiatric services to patients across the country, particularly in rural America. And I think an important, we think an important component of telemedicine would be the availability of long acting injectables as a compliment to the telemedicine that could be dispensed across the country in different sites of care. So this is one of those fundamental changes that we're interested in driving in both psychiatry and in addiction.

30:50 Got it. And then one quick question for Jim. You had talked about the mixed shift in terms of payers and consolidation of Medicaid-type payers, etc. Are we about to anniversary or done with that? Or where along the course of those transitions are we? Is that going to continue to be the case? Or is there any chance that that lessens at all, particularly as we get towards the midpoint and second half of this year? Thank you.

31:14 Yeah, thanks, Chris. And, you know, specifically, it affected our gross tenets, you know, this year compared to last year with Aristotle. I think the major consolidation has probably come through the providers of Medicare and Medicaid services from a commercial side that, you know, the BMS have gotten bigger. And, and I think from a, it's hard to predict what's going to happen in the future. But I think those impacts really are, we've seen. and we might see an you know another point or two in gross to net through the course of the year for aristata but we don't see a major change so i think we've seen the the major impact of those consolidations on the aristata side great thank you i'll get back in the queue you're welcome thanks chris thank you our next question comes from the line of jason gerberry with bank of america please proceed with your question hey uh good morning thank you for taking my uh questions um Just a follow up on Vivitrol first.

32:15 You mentioned new patient starts as being more negatively impacted and I'm just curious, you mentioned closure of clinics. I'm just curious how adherence is looking from your perspective with pre-existing patients being able to come back. I know that you talked about the clinics being a longer term opportunity, but in the near to medium term, How are patients managing their follow-up treatments and is that also being negatively impacted?

32:46 Hi Jason, this is Todd. Glad you asked that as well. Something that we're watching very closely. A couple different questions in that. It's a little too early to determine if there's an impact on adherence. Vivitrol adherence is somewhere in the range of around 3.9 to 4. historically over time. So based on this situation, we don't have a good sense that that has actually changed at this point right now. A lot of the disruptions that we are hearing and seeing right now are really regionally based. And I think the best assessment that I would point you to is really the hotspot states, as I mentioned in my prepared remarks. New York, California, Florida, Michigan, some of those areas you know we are very close to our customers across the U.S.

33:39 but in some of those areas we are hearing more disruption than in other parts of the country as well and so it really depends upon the state, the site of care that the physician is practicing in and also the patient profile. We do know that the Vivitrol patient is a very committed patient and so we're still very encouraged by that because that's a patient that's made a commitment to the product as well. And so we're going to be monitoring adherence. We're going to be monitoring closures at the state level. And then also when the policies at the state level start to loosen up and we start to see patient flow start to increase more specifically, hopefully in the coming weeks and months. Great. And if I could just follow up, the comment about closure of addiction clinics, is this something that you'd expect to be more temporary.

34:32 Can you put any metrics around this? I'm just curious, like dental offices, would we expect a reopening of these offices once the economy's reopened? And then my second follow-up to that is just thinking about sales and marketing that's more discretionary in nature, the spending, how you can potentially flex down spend you know during during this period or do you have to actually step up your discretionary marketing spend because you don't have that physical touch point with the physician?

35:05 Yeah listen again I'm glad you asked that as well too. I think I think the first thing to keep in mind how we think about this is that Vivitrol will continue to be a very important element of our nation's response to the opioid crisis. and we do see growth opportunities for Vivitrol in the future as well so we do believe our going assumption right now is that this is an acute issue right now that's really being driven by the pandemic at this point as well it's hard to tell so your question on quantification is very difficult for us to quantify that at this point hopefully in the future we will be able to provide more data on that as well but we do believe that this is a little bit more of an acute issue as well and your point on discretionary spend and investment with our commercial resources and marketing dollars.

35:58 As you heard from my prepared remarks and also from Rich as well, we shifted very, very quickly in the latter part of March to make sure that we were shifting our resources to support patient needs. And we really saw that in three areas. Number one, the first area is around making sure that we're maximizing virtual engagement. and that we're being relevant to our customers through the programs that we're offering them. Secondly is that we're expanding access to injections and we're doing a lot of work in that area right now and we're enthusiastic about that work. And then thirdly is building new capabilities such as our digital presence as well. And so we have increased some resources in the digital domain to make sure that we're communicating the value proposition of both brands of Vivitrol and Aristata to healthcare providers but also to patients as well.

36:51 Got it, thank you so much.

36:54 Hey Jason, it's Rich. I just want to build on something Todd said that while it's not something to focus on in Q2, we have had conversations with major providers and payers and public health officials about the aftermath of COVID-19. And right now what's happening in homes around the country is alcohol and opioid use is growing. as people deal with social isolation and dealing with the consequences of the way that people are living their lives right now. There's a serious concern and to Todd's point, Vivitrol is a mainstay medicine in the treatment of these conditions. So while we can't predict when this is going to over, there is going to be a tail to this sequestration period and it's going to be it's going to be quantified in the rates of alcohol and opioid use disorders as well as other psychiatric manifestations.

37:54 Thank you.

37:56 You're welcome. Thank you. Our next question comes from the line of Corey Kazimoff with J.P. Morgan. Please proceed with your question. Hey, good morning guys. Thank you for taking my questions. First one I wanted to ask you is for the first quarter did you see any Early pull through of either Aristata or Vivitrol that helped with the quarter. Were there any other COVID-19 related tailwinds for the commercial businesses we've seen some other companies talk about so far this earnings season? And I have a follow up.

38:24 Yeah. Hey, Corey, it's Jim. You know, we have not seen dramatic changes with the COVID tailwinds, let's say, in the beginning. You know, inventory levels actually came down as we would have expected from Q4 to Q1. So I think we can say that it was really the focused effort of Todd and the commercial teams and really nice underlying unit growth. You know, that 47% growth compared to last year that we saw in Aristata and the 13% growth that we saw in Vivitrol. I think, you know, we're off to a good start this year. And, you know, like many companies, I think, and many people across the country before we got the surprise from the COVID pandemic. Okay.

39:05 Yeah. Corey, if I could just add to Jim's comments. as well too. Our focus for the year was to start strong and really focus on commercial execution. And so we are seeing some encouraging signs and also some encouraging feedback from our customers around the value proposition for 1064, our two-month dose offering as well. It's a major underpinning of our commercial strategy as well, so 1064 plus initio. It's a little early to quantify it, but we are seeing that the distribution of doses is directionally moving in the right direction with 1064. And to Rich's earlier comment as well, too, is we are seeing some encouraging signs and trends with alcohol for Vivitrol as well, too. So we are optimistic about that.

40:00 Okay, that actually was going into what my second question was going to be in terms of the commentary around the two-month dosing and that it's not surprisingly resonating well, but I was curious if you're seeing an uptick in the actual adoption, but even maybe going a step beyond that, what's the feasibility, if at all, of implementing at-home nursing to administer your products, and do you think payers would be receptive to something like that?

40:33 Yeah, absolutely. So we're looking at the feasibility of a number of opportunities to expand injection for patients. Our number one focus, obviously, is to be patient-focused, patient-centric, to make sure that patients have access to our medicines as well, too. So we're looking at all kinds of alternate site injections as well, too. I can't give you anything firm at this point. on strategically where we go, but we are looking at a number of different options.

41:06 Okay. Hey, Corey, it's Rich. I was beginning to answer that before, but I was on mute, so thanks, Todd, for jumping in. It's the sign of the times, isn't it? We are having some really interesting conversation with large payers and others in this moment as we look around the country. There are islands of best practices around the country where things like at-home programs uh care for addiction uh are being implemented in pilot programs and you can see that the data are being developed in certain these pilot programs and we're we're talking to to major payers about consolidating these these now anecdotal or even small pilot programs into what could represent a model of comprehensive care within a major payment system so long answer to a simple question but absolutely yes there's there's there's an opportunity here over time to change the way that some of these conditions are treated across the country okay thanks guys appreciate the answers thank you our next question comes from the line of Omar Rafa with Evercore ISI please proceed with your question hi thanks so much for taking my question maybe first on 3831 and I had two follow-ups Richard you mentioned FDA's I just want to make sure I heard it right.

42:30 FDA has told you guys that there's an adcom? Is that right?

42:33 Yeah, they told us earlier that we should plan for an adcom, but they haven't given us any specifics about the content or the format yet. So it's almost like a placeholder. Count on it. You're not not having one as of now. Count on it. Right. So I guess, Richard, I was just thinking about some of the recent approvals and ITCI, Intercellular, was told they might need an adcom given some of the preclinical things that they were looking at it never ended up happening but generally speaking the trend has been not to have adcoms and considering samidorphine was already reviewed as part of the 5461 review i'm just trying to understand what the issue could be has an issue come up during the review no there's been no issue come up in the review as i mentioned earlier though

43:19 because it's an interesting label, right? Because it's a 505 off of leveraging olanzapine safety efficacy information as well as B1 level of clinical trials that we ran ourselves, yet we're looking for also a differentiated weight claim because of obviously the profile of . So metabolism and endocrines in the review as well. so when we put together the integrated summary of safety integrated summary of efficacy it's with the knowledge that will be reviewed by both of those divisions so we don't know yet what if there is an issue or what the issue may be or if it's more of a labeling discussion we just don't know yet but we'll we'll give you guys more information as we get more information through the review got it and Richard maybe this is for you and Jim both of you um as I look at and I was just trying to crunch the numbers and I guess what I'm arriving at is um If the revenues track around a billion dollars total revenues in that scenario, and let's say the costs track slightly lower than the loan of the guidance you guys previously gave out, the cash burn will be about $100 million.

44:30 If the revenues are lower and or the cash op-ex isn't managed more carefully, cash burn could approach $200 million plus quite easily. So the question I have is, your net cash, cash minus debt right now, is $273 million right now. Do you have a number in mind of how much of your net cash balance are you willing to spend this year? And I guess what I'm really getting at is your OPEX expectations because that's something you can control.

44:56 I'll give you the first answer and then I'll let Jim answer as well. You just have to be real careful right now projecting to the end of the year based on circumstances of COVID-19. We think the economy is going to open back up and there's going to be a resurgence of access to our medicines and need for those medicines. With that said, we, as Jim said in his remarks, we have to pay attention to that top line so we can modulate the spend to make sure that we don't burn significant amount of cash this year. But I'll let Jim give you a little bit more color on that.

45:31 Sure, thanks, Umar. And I think that, you know, that point is exactly right. You know, we've seen three or four weeks of a dramatic impact in COVID with social distancing and shelter in place activities, you know, particularly in, you know, as you know, in New York and the surrounding regions. But as we come back out, the treatment of addiction and serious mental illness, you know, we don't think is going to be effective long term and may in fact have a significant rebound. So the short term changes is why we've currently suspended guidance. And if we see those changes dramatically impact our revenue going forward, we'll absolutely be active in terms of managing the cost line. There's a lot we can do. Obviously things are changing like travel and in-person meetings on the SG&A side.

46:19 There's launch costs and expectations around 3831 and what we invest in that as we move forward through the course of the year. And then there's obviously gonna be an impact on clinical trials as we mentioned. We hope that's counted in the terms of months or weeks in terms of the delay of clinical studies. But again, if this COVID-19 pandemic goes longer than we expect, those costs are going to be modulated as well. So we have a lot of things we can control. And our target this year, as you know, was for a $50 million positive non-GAAP net income around the ranges of our guidance. We've been impacted by COVID in the short term, and we're going to watch that very, very carefully and take active steps depending on what happens.

47:06 Right. But Jim and Rich, if I may, just to follow up on that, is it reasonable for us to assume that of the net cash balance of 273, there is a number in mind, there is a threshold in mind for both of you, beyond which you're not willing to burn more? Like, is it fair to assume you're not going to burn more than, let's say, 200 million in cash this year?

47:26 Yeah, I wouldn't put a number on it at this moment, but the answer to that is yes. Got it. Thank you very much. Thank you. Our next question comes from the line of Paul Matisse with Stifel. Please proceed with your question. Great. Thanks so much for my questions. On Vivitrol and Aristata, historically in the non-kind of pandemic world that we lived in only a few months ago, What was the historical annual persistence rate for these medications? And I guess what I'm trying to get at is when you think about 2019 or 2018, how much were these medicines reliant on new patient starts even just to keep revenues stable, let alone growth? And I guess when you look forward to the later parts of this year, do you worry at all that given the kind of looming threat of a second wave that new patient starts for these medications could be more durably impacted given that you know while the oral alternatives in certain contexts aren't ideal they are there and then i have one follow-up thanks so much yeah paul this is todd i'll i'll take the first part of that as well so you know we watched the persist persistency curves pretty closely with both brands

48:44 As I said earlier, for Vivitrol, it's approximately 3.9. For Aristata, a little bit better than that, around 5, which is pretty consistent. These are average duration of treatment a month, is that right?

48:58 That's right. Thank you for the clarification. Average duration of treatment a month, which is pretty consistent with what you would see with longer-acting injectables. In fact, we start to see a little bit of a move with Aristata as we start to get More utilization with the 1064, which is a two-month dosing option as well. And that's in line with what our expectations are as well strategically. I think the big question you're talking about is just patient flows. What is the anticipation with patient flows? And for us, the way we think about that across the organization is that we are in a short-term disruptive period right now. These are very vulnerable patients. with serious mental illness and addiction, they need services, they need treatment, they need variable options as well too. So we fully believe that these patients will come back to treatment as soon as the social distancing practices are lifted, as soon as access is available to them as well too.

49:58 To your earlier comment, Vivitrol is a little bit more vulnerable to new patient flows. The new patient flow for Vivitrol is approximately 20 to 25%. For Aristata, it's around 9% to 10%. We watch that with NBRXs and also with NRXs as well, too. And so we watch it very closely, but we think we're in a short-term situation here. We also believe that a lot of the best practices that we're going to see across the healthcare sector in general and in life sciences will apply into the fall, into the winter as well. So companies and patients and healthcare providers will actually get, we believe, will get much better at how to manage patient flows, how to manage their offices, how to manage patient appointments and so forth as we move through this period of time right now.

50:46 And that was one of the comments that Rich made earlier as well, too. You know, we fully plan on leveraging the best practices and the capabilities that we're developing right now as a commercial organization, and we'll actually apply those even to the launch of 3831 as well. got it okay if I could clarify on your comments around Vivitrol so average duration of treatment historically is four months does that mean half of patients just continue by month four in which case you kind of need to keep returning over the patient base and I guess maybe one other way to think about it because I wasn't sure the context around the the other numbers you gave at the second percentages but Maybe in 2019, I don't know if you can say this, but what percent of Vivitrol revenues were from new patient ads?

51:36 I don't have that level of detail right now, but the way that I would say to think about this as well is we see the greatest drop-off of persistency after the first and second month. Once a patient stays on therapy, for at least two to three months, they tend to have a longer duration of therapy. So it's typically the first month that we see the greatest drop off. One of the predominant reasons why, and you've heard us talk about this on previous calls as well, is around continuity of care. It's really important that the system is set up to treat these patients, these addiction patients that come through inpatient services, that are in residential treatment centers as well too, that they have a solid continuity of care plan as well too. So we do put a lot of emphasis and a lot of thinking around how do we support a strong continuity of care.

52:33 Okay, thanks. Maybe just one last question. For detoxing a new patient before they go on to Vivitrol, you talked about these specific addiction centers. is that largely the context in which this sort of uh is that largely the context in which the pre-treatment detox occurs or or is it ever occurring also just kind of in in in general hospital units where you might actually be competing for space um from a COVID surge yeah that's that let me spend just a few minutes on that you're thinking about it the right way predominantly you know detoxification prior to

53:13 Initiation with Vivitrol would happen in an inpatient unit. Typically that's where you see that. And so we do see ramifications that are very consistent with the broader healthcare landscape around social distancing, the surge in patients for COVID-19 that are in the hospital sector as well. But I will also let you know that there is an emerging trend and some of the emphasis that we place is how do we establish the right environment for outpatient detox as well. you know as we've talked about in the past we we have a you know a strategic approach within our market access group regarding making sure there's a proper environment for reimbursement of outpatient detox and that is a strategic pillar for us but to your point the majority of the detox has happened in the inpatient setting as well too and that includes you know various different settings of care not only from inpatient hospital but also in the criminal justice setting as well Got it. Okay. Thanks so much for the color.

54:13 Appreciate it.

54:14 Thanks, Paul. Melissa, before we take the next question, I ask that the remaining folks in the queue limit themselves to one question so we can get to as many people as possible in our remaining time. Thank you. Our next question comes from the line of Brandon Foulkes with Cantor Fitzgerald. Please proceed with your question. Hi, thanks for taking my question. Maybe just quickly on Vivitrol, given the COVID-19 pandemic, are you seeing any funding at the state level or potential funding you had for 2020 being redirected towards COVID-19 versus addiction? And when do you think we get that bonus of funding for addiction post the COVID pandemic that you've talked about with these knock-on effects?

55:05 So, hey, Brendan, I'll start and I'll ask Todd for any color he might be seeing. But, you know, the federal funding that's been allocated to address the opioid crisis is flowing from the federal government appropriations then into the states. Then the states have, within the context of the statute, the ability to deploy those monies for the treatment of opioid and other addictions. So we don't see any interruption in that allocated funding, which is substantial coming from the federal government. on the front lines at the state level. We haven't seen it manifest itself yet, but Todd, do you have any comment on that?

55:42 No, I think you've covered it, Rich. Okay. Great, thank you.

55:48 Thanks, Brandon. Thank you. Our next question comes from the line of Beran Amin with Jefferies. Please proceed with your question. Yeah, hi, guys. Thanks for taking my questions. On Aristata, you cited 43% year-over-year growth on prescriptions. Can you just provide, in terms of that growth, what came from new patient starts versus switches? And on patient switches, were these from other LAIs or oral psychotic?

56:20 Yeah, Aaron, this is Todd. I'll start with that as well, too. So new patient starts, the way we think about new patient starts is really in two domains. NRXs are new prescriptions, which we're very pleased with. with hitting an all-time high of 10%. But then more specifically, one of the metrics that we follow very closely is new to brand share. These are patients that haven't been on the product for a certain period of time. And as I said in my prepared remarks, we've hit all-time highs at 13.2% right now. And it's an all-time high for the brand at this period of launch as well, and we're very encouraged with that. Our sense right now, our data, and even the qualitative feedback that we received through our research says that a substantial majority of that is now coming through 1064, which is right in line with what our strategy is at this point right now. So we feel really good about that.

57:21 Great. Thank you. Thank you. Our next question comes from the line of Mark Goodman with SVB Learing. Please proceed with your question. Yes, morning. Can you just clarify one of your previous comments? I think someone asked about Vivitrol and Aristata sales in the first quarter, and if there was any, I guess the question is, was there any pull-through into the quarter? We're hearing from multiple pharma companies that there's a huge amount of sales that they're booking in the first quarter that they, you know, for multiple reasons, obviously, and so it sounds like you believe Vivitrol and Aristota did not have any of that in the quarter and I was wondering if you could just comment on that as well as the manufacturing royalty revenues because obviously that has implications for how you're going to be booking revenues going forward so just give us a sense of what J&J is telling you of you know Invega and all those products did they get pulled through I mean can you just give us a sense of what's going on there so we understand That trend.

58:23 And could you also just clarify your comment about the 25% below expectations on Vivitrol for April? Below what expectations? Were you expecting it to be down 25% and it was worse? Or just maybe you could help us with that number. Thanks.

58:37 Sure, Mark. It's Jim. Good morning. yeah and I think so what you know it's very hard to understand exactly what's happening right because we're we're three weeks in we haven't had all the reports three weeks in April so we haven't seen all the reports that we would look at some of those are going to be coming out and you know in early May in terms of demand sales and things like that but as we look at our orders out to our wholesalers you know again the best we can do is compare it to q1 of last year and the trends that we saw through the quarter were pretty consistent for both Vivitrol and Aristana. And again, the inventory drawdown compared to where we sat at December of 19 was strong and consistent. So we're down roughly 6,000 units in inventory from where we were with Vivitrol and roughly 3,500 units from where we were with Aristana.

59:32 So we think that those orders out to the wholesalers were you know again they were consistent through the months and we had a very strong first quarter you know as Todd was discussing the move towards the two months I mean injection for aristata I mean I think that's an interesting anecdote that we're hearing from the field is that you know perhaps the shift to a two-month injection is part of the thinking and you know again the shift to a monthly injection if you're not going to be able to see the patient for some period of time Actually, the benefit of a monthly LAI, either for a month or two months, actually is a real one for patients and for physicians in this scenario. So I just want to make sure I get your questions. So I think we saw consistent growth in Vivitrol and Aristata, again, compared to what we saw last quarter. From J&J, we really haven't had information that there's been a change in their growth rates with Sistena.

1:00:35 We saw consistent growth again with what they saw in the quarter. So we haven't seen any difference with the long-acting injectable part of that business from J&J either. So I think we just had a strong first quarter as we headed into the COVID impact. And when it comes to our comments on the 25% decline with Vivitrol, that was based on our expectations at the beginning of the year for April. So the growth we saw in the first quarter, the second quarter is typically one of the strongest quarters we have. So we expected to see continued growth in Vivitrol and the trends there. And in the first three weeks in April, we've seen, you know, again, that roughly 25% change in terms of orders. Very hard to predict how long that's going to last, what the duration will be. Again, we think it's very focused.

1:01:24 We know it's very focused in the northeast around New York, New Jersey, Massachusetts. and we'll be watching those trends as we go through the rest of the year. So hopefully that's a little bit more clarity. Thanks. You're welcome. Thank you. Our next question comes from the line of Emile Devon with Mizuho. Please proceed with your question. Great. Thanks for all the color on the call. Thanks for taking my question. So just maybe a couple to clarify in 4230 when you mentioned the activation of select XUS sites in Asia Pac and Europe. I'm just curious, is that a new sort of change because of the dynamics in the U.S. right now that you're sort of expanding out sites? Or was that already sort of planned and you're just sort of highlighting that it's still taking place in the second quarter? And then you mentioned the data release later this year. I'm wondering if you can just give a little more expectations there.

1:02:17 Obviously, things are fluid, but should we expect something around the 60 timeframe or any other sort of time points that we should be looking out for the next data set from that product? Thanks.

1:02:29 Mordenbaum with Rich. No, the Asia Pacific Europe site expansion has always been part of the part of the plan, particularly as we as we look at the the the artistry one intravenous protocol for looking to monotherapy in renal and melanoma. A lot of the expectation for that enrollment comes from the ex US side. So Western Europe is still pretty much quiet right now. But Asia Pacific and other parts of Europe are starting to come back up. So We have ambitious plans for Q1 and Q2 site activations. Those have been shifted a little bit, but they're still very much part of the plan we came up with last year. And we'll see, certainly we expect to have data around the CITC in the September timeframe and we'll present data. We're all pretty fluid right now in trying to understand how these medical meetings are going to be conducted, when abstract deadlines are going to be firmed up. They're fairly flexible right now.

1:03:26 So we're accumulating data across the program and we'll certainly by the fall be in a position, I think, to provide a significant update. Thank you. Our next question comes from line of Akash Tiwari with Wolf Research. Please proceed with your question. Hey guys, thanks so much. Can you give any more color on the 3831 potential ad comp? How many patients in the 3831 trials were on background opioids? And were there any serious adverse events related to opioid withdrawal caused by samydorphin that you observed? And just on Tecfidera, given the Tecfidera patent win, do you feel like there needs to be a reset on royalty estimates for rumority going forward? It looks like you know, consensus is is baking in like a $400 million Lumerity drug next year. So do you think maybe the launch expectations need to be a bit more tempered? Thank you.

1:04:28 Hey, Akash, I'll take the beginning of that. The 3831, no, I don't have the specific numbers on people on background opioids, but no, there's no issue in the NDA that is appearing in the data that says anything to do with samudorphins, opiate receptor antagonist properties contributing any safety signals. No, that's not the issue. I think it's more what I was responding to when I answered a numerous question about the new drug application. The first quarter sales of Vumerity were de minimis and Biogen is obviously in charge of this. We did the deal with Biogen because of their marketing and commercial prowess in MS. This drug has very nice features.

1:05:16 and so we're going to be looking for more growth out of that. I'll let Jim and Sandy comment on the expectations because I don't actually know what street models are for it this year but we expect it to grow and we think it's an important product and we're looking for more performance from Biogen as the year plays through. Got it.

1:05:39 Yeah, I think the models for most of the models that incorporate numerity are from Biogen's analysts So we'll be looking to see their new models come in over the next few days. So I don't want to speculate on what that range looks like right now. We have time for one more question, please, Melissa. Thank you. Our next question comes from the line of Douglas So with HC Wainwright. Please proceed with your question. Hi, good morning. Thanks for taking the questions. I know you spoke about some of the geographic impact on Vivitrol in terms of regions most affected by COVID. Just curious, are you seeing any regional trends on the impact for Aristata so far? Just so we can think about how it might play forward as certain states start to use restrictions.

1:06:29 Thank you.

1:06:31 Yeah, Doug, this is Todd. You know, we're seeing some similar feedback from customers regarding social distancing practices. But there is a nuance, a difference. The difference that we're really watching with Aristotle more so is the ability of clinics to still accept patients when they originate for injection. So watching the broader trends within psychiatry, psychiatry is one of the specialties that's adopted telemedicine more rapidly than other therapeutic areas. By some estimates, psychiatrists will report that they practice telemedicine at a rate of around 80%.

1:07:16 Our feedback, the qualitative feedback that we consistently receive is even though there is a practice of telemedicine, a lot of the sites that patients will originate to accept injections at the physician offices are still open. and still available. And so right now, we don't see as dramatic of a geographic disruption for Aristotle like we do with Vivitrol. Okay, great. Thank you very much.

1:07:47 Okay, great. Thanks everyone for joining us on the call this morning. If you have any follow-up questions, please don't hesitate to reach out to us at the company. Thank you very much. Thank you. This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.

Follow Alkermes PLC into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Sandra Coombs

Vice President, Investor Relations

Richard Pops

Chief Executive Officer

Todd Nichols

Senior Vice President, Sales and Marketing

Jim Fradies

Chief Financial Officer

More from Alkermes PLC